-
Mashup Score: 0
An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods Using EULAR standardised operating procedures, the EULAR task force undertook a…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#EULAR recommendations for management of ANCA-associated vasculitis eosinophilic granulomatosis polyangiitis eGPA ➡️ Therapy for severe AAV is #cyclophosphamide or #rituximab plus glucocorticoid 👉🏼https://t.co/MVrql0au27 Via @ARD_BMJ @eular_org Via Prof Raashid Luqmani #BSR23 https://t.co/Xz80IYGTWM
-
-
Mashup Score: 1
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods Using EULAR standardised operating procedures, the EULAR task force undertook a…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#EULAR recommendations for management of #ANCA-associated vasculitis granulomatosis polyangiitis (GPA), microscopic polyangiitis (MPA) ➡️ Therapy for severe AAV is #cyclophosphamide or #rituximab plus glucocorticoids 👉🏼https://t.co/MVrql0au27 Via Prof Raashid Luqmani #BSR23 https://t.co/QimOnOvGTu
-
-
Mashup Score: 0
On the heels of a positive ODAC vote, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is now FDA-approved.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The #FDA has granted approval to polatuzumab vedotin-piiq in combination with #rituximab, cyclophosphamide, doxorubicin, and prednisone for #DLBCL. #lymsm https://t.co/1BGDNFkMJx
-
-
Mashup Score: 0
Results of a phase 2 trial indicate that BTK inhibitor ibrutinib plus lenalidomide and rituximab led to antitumor activity with durable responses among patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Recent #Hematology news findings indicate that #ibrutinib, a #BTK inhibitor, plus #lenalidomide and #rituximab demonstrated antitumor activity with durable responses among patients with R/R #DLBCL. Read more here: https://t.co/6ZQEhsYkNg @uthsc https://t.co/xy2MAHC1m1
-
-
Mashup Score: 1Neurology Video Journal Club: Myasthenia Gravis / ALS / Neuromuscular | American Academy of Neurology Journals - 1 year(s) ago
Sponsored by unrestricted funds by argenx. Articles and discussants selected by the editors of Neurology. Latest Episode Join us for this and future episodes to learn from experts as they discuss recent Neurology journal articles and hot topics in the field of neurology. Articles and discussants are selected by the editors of Neurology. In this episode of Neurology Video Journal Club,…
Source: www.neurology.orgCategories: Latest Headlines, NeurologyTweet-
Neurology Video Journal Club: Dr. Henry Kaminski and Dr. Sarah Wright discuss an article published in Neurology on #rituximab therapy in the treatment of juvenile myasthenia gravis. Watch Now: https://t.co/y8GRrcAi1M Article Link: https://t.co/xgqDR0VKEj #NeuroTwitter @GWSMHS https://t.co/n1wDxzlmVK
-
-
Mashup Score: 0
Optimal induction strategy in highly sensitized kidney transplant recipients (KTRs) is still a matter of debate. The place of therapies, such as plasma exchange and rituximab, with potential side effects and high cost, is not clearly established. We compared two induction strategies with (intensive) or without (standard) rituximab and plasma exchange in KTRs with high levels of preformed DSA…
Source: FrontiersCategories: Latest Headlines, TransplantationTweet-
Intensive induction therapy including #rituximab and #plasma #exchange in highly sensitized kidney transplant recipients is not associated with better #graft #survival but may delay biopsy-proven #rejection https://t.co/TVlxb9nT85 https://t.co/0nAWhkZm4N
-
-
Mashup Score: 0Exposure to Rituximab Biosimilars did not Increase Hypersensitivity Reaction Hospitalizations - 1 year(s) ago
A recent study found no association between exposure to rituximab biosimilars and hospitalization for hypersensitivity reactions compared to the biologic at initiation, at switch, or over time.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
A recent study found no association between exposure to #rituximab #biosimilars and hospitalization for hypersensitivity reactions compared to the biologic at initiation, at switch, or over time: https://t.co/Oz7CHlU3fU
-
-
Mashup Score: 0
No differences in adverse events, including infusion-related reactions, infections, and hypogammaglobulinemia, were reported among patients receiving rituximab and the biosimilar, CT-P10.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
No differences in adverse events, including infusion-related reactions, infections, and hypogammaglobulinemia, were reported among patients receiving #rituximab and the #biosimilar, CT-P10. https://t.co/dtz8OIh7a4 https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0
Proof-of-concept trial, but ‘future is bright for chemotherapy-free approaches,’ he says
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
How do you account for the depth of response with #rituximab, #lenalidomide, and #ibrutinib? #oncology @ASCO #ASCOReadingRoom Read more: https://t.co/gkCyU3t13h https://t.co/MuEn84hxaq
-
A review of the MURANO trial of #venetoclax + #rituximab in patients with relapsed/refractory #CLL by @calliecoombsmd of @UCIrvineHealth. #leusm https://t.co/EmgvXA78ZC